Is there a link between inflammation and fatigue in multiple sclerosis?

References

• SospedraMMartinRImmunology of multiple sclerosisAnnu Rev Immunol20052368374715771584
   PubMed Web of Science ®Google Scholar
• DendrouCAFuggerLFrieseMAImmunopathology of multiple sclerosisNat Rev Immunol20151554555826250739
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet20083721502151718970977
   PubMed Web of Science ®Google Scholar
• ChalahMARiachiNAhdabRCréangeALefaucheurJPAyacheSSFatigue in multiple sclerosis: neural correlates and the role of noninvasive brain stimulationFront Cell Neurosci2015946026648845
   PubMed Web of Science ®Google Scholar
• CentonzeDMuzioLRossiSFurlanRBernardiGMartinoGThe link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosisCell Death Differ2010171083109119927157
   PubMed Web of Science ®Google Scholar
• AyacheSSChalahMAFatigue in multiple sclerosis: insights into evaluation and managementNeurophysiol Clin20174713917128416274
   PubMed Web of Science ®Google Scholar
• FrealJEKraftGHCoryellJKSymptomatic fatigue in multiple sclerosisArch Phys Med Rehabil1984651351386703889
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementBMJ2009339b253519622551
   PubMed Web of Science ®Google Scholar
• TsujinoNSakuraiTRole of orexin in modulating arousal, feeding, and motivationFront Behav Neurosci201372823616752
   PubMed Web of Science ®Google Scholar
• KiyashchenkoLIMileykovskiyBYMaidmentNRelease of hypocretin (orexin) during waking and sleep statesJ Neurosci2002225282528612097478
   PubMed Web of Science ®Google Scholar
• GrossbergAJZhuXLeinningerGMInflammation-induced lethargy is mediated by suppression of orexin neuron activityJ Neurosci201131113761138621813697
   PubMed Web of Science ®Google Scholar
• OkaYKanbayashiTMezakiTLow CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosisJ Neurol200425188588615258796
   PubMed Web of Science ®Google Scholar
• KatoTKanbayashiTYamamotoKHypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesionsIntern Med20034274374512924505
   PubMed Web of Science ®Google Scholar
• PapućEStelmasiakZGriebPPawełGRejdakKCSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patientsNeurosci Lett201047491220193740
   PubMed Web of Science ®Google Scholar
• ConstantinescuCSNiepelGPattersonMOrexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepinessJ Neurol Sci201130712713121605873
   PubMed Web of Science ®Google Scholar
• BoddumKHansenMHJennumPJKornumBRCerebrospinal fluid hypocretin-1 (orexin-a) level fluctuates with season and correlates with day lengthPLoS One201611e015128827008404
   PubMed Web of Science ®Google Scholar
• LimonePFerreroBCalvelliPHypothalamic-pituitary-adrenal axis function and cytokine production in multiple sclerosis with or without interferon-β treatmentActa Neurol Scand200210537237711982488
   PubMed Web of Science ®Google Scholar
• GrasserAMöllerABackmundHYassouridisAHolsboerFHeterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosisExp Clin Endocrinol Diabetes199610431378750568
   PubMed Web of Science ®Google Scholar
• MichelsonDStoneLGallivenEMultiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis functionJ Clin Endocrinol Metab1994798488538077372
   PubMed Web of Science ®Google Scholar
• BerghFTKümpfelTTrenkwalderCRupprechtRHolsboerFDys-regulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MSNeurology19995377277710489039
   PubMed Web of Science ®Google Scholar
• YsrraelitMCGaitánMILopezASCorrealeJImpaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosisNeurology2008711948195419064876
   PubMed Web of Science ®Google Scholar
• MeliefJde WitSJvan EdenCGHPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matterActa Neuropathol201312623724923812288
   PubMed Web of Science ®Google Scholar
• HuitingaIErkutZAvan BeurdenDSwaabDFImpaired hypothalamus pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesionsAnn Neurol200455374514705110
   PubMed Web of Science ®Google Scholar
• HeesenCGoldSMRajiAWiedemannKSchulzKHCognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosisPsychoneuroendocrinology20022750551711912002
   PubMed Web of Science ®Google Scholar
• HeesenCNawrathLReichCBauerNSchulzKHGoldSMFatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?J Neurol Neurosurg Psychiatry200677343916361589
   PubMed Web of Science ®Google Scholar
• HeesenCSchulzKHFiehlerJCorrelates of cognitive dysfunction in multiple sclerosisBrain Behav Immun2010241148115520621641
   PubMed Web of Science ®Google Scholar
• GoldSMKrügerSZieglerKJEndocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depressionJ Neurol Neurosurg Psychiatry20118281481821296901
   PubMed Web of Science ®Google Scholar
• AkcaliAZenginFAksoySNZenginOFatigue in multiple sclerosis: is it related to cytokines and hypothalamic-pituitary-adrenal axis?Mult Scler Relat Disord201715374128641771
   PubMed Web of Science ®Google Scholar
• Shishioh-IkejimaNOgawaTYamagutiKWatanabeYKuratsuneHKiyamaHThe increase of alpha-melanocyte-stimulating hormone in the plasma of chronic fatigue syndrome patientsBMC Neurol2010107320731841
   PubMed Web of Science ®Google Scholar
• GottschalkMKümpfelTFlacheneckerPFatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosisArch Neurol20056227728015710856
   PubMed Web of Science ®Google Scholar
• KümpfelTSchwanMWeberFHolsboerFTrenkwalderCBerghFTHypothalamo-pituitary-adrenal axis activity evolves differentially in untreated versus treated multiple sclerosisPsychoneuroendocrinology201445879524845180
   PubMed Web of Science ®Google Scholar
• DunnAJEffects of the IL-1 receptor antagonist on the IL-1- and endotoxin-induced activation of the HPA axis and cerebral biogenic amines in miceNeuroimmunomodulation20007364510601817
   PubMed Web of Science ®Google Scholar
• PowellDJMoss-MorrisRLiossiCSchlotzWCircadian cortisol and fatigue severity in relapsing-remitting multiple sclerosisPsychoneuroendocrinology20155612013125817406
   PubMed Web of Science ®Google Scholar
• ClowAHucklebridgeFStalderTEvansPThornLThe cortisol awakening response: more than a measure of HPA axis functionNeurosci Biobehav Rev2010359710320026350
   PubMed Web of Science ®Google Scholar
• VoglDFalkWDornerMSchölmerichJStraubRHSerum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormonesJ Rheumatol20033026927512563679
   PubMed Web of Science ®Google Scholar
• TengstrandBCarlströmKFellander-TsaiLHafströmIAbnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and current degree of inflammationJ Rheumatol2003302338234314677174
   PubMed Web of Science ®Google Scholar
• TéllezNComabellaMJuliàEFatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosteroneMult Scler20061248749416900763
   PubMed Web of Science ®Google Scholar
• CalabreseVPIsaacsERRegelsonWDehydroepiandrosterone in multiple sclerosis: positive effects on the fatigue syndrome in a non-randomized studyKalimiMRegelsonWThe Biological Role of Dehydroepiandrosterone (DHEA)Berlinde Gruyter199095100
   Google Scholar
• BiberacherVSchmidtPSelterRCFatigue in multiple sclerosis: associations with clinical, MRI and CSF parametersMult Scler Epub201751
   Google Scholar
• BrennerPGranqvistMKönigssonJal NimerFPiehlFJokinenJDepression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkersPsychoneuroendocrinology201889535829324301
   PubMed Web of Science ®Google Scholar
• RovarisMBarnesDWoodrofeNPatterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium enhanced brain MRI and cytokine measurement in different clinical subgroupsJ Neurol19962435365428836944
   PubMed Web of Science ®Google Scholar
• KhademiMWallströmEAnderssonMPiehlFDi MarcoROlssonTReduction of both pro- and anti-inflammatory cytokines after 6 months of interferon β-1a treatment of multiple sclerosisJ Neuroimmunol200010320221010696916
   PubMed Web of Science ®Google Scholar
• BaraczkaKPozsonyiTSzütsIOrmosGNékámKIncreased levels of tumor necrosis alpha and soluble vascular endothelial adhesion molecule-1 in the cerebrospinal fluid of patients with connective tissue diseases and multiple sclerosisActa Microbiol Immunol Hung20035033934814750436
   PubMedGoogle Scholar
• RudickRABarnaBPSerum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigueArch Neurol199047254255
   Google Scholar
• FlacheneckerPBihlerIWeberFGottschalkMToykaKVRieckmannPCytokine mRNA expression in patients with multiple sclerosis and fatigueMult Scler20041016516915124762
   PubMed Web of Science ®Google Scholar
• KierkegaardMLundbergIEOlssonTHigh-intensity resistance training in multiple sclerosis: an exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognitionJ Neurol Sci201636225125726944158
   PubMed Web of Science ®Google Scholar
• Alvarenga-FilhoHSacramentoPMFerreiraTBCombined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediatorsJ Neuroimmunol2016293919927049568
   PubMed Web of Science ®Google Scholar
• MokhtarzadeMRanjbarRMajdinasabNPatelDShamsiMMEffect of aerobic interval training on serum IL-10, TNFα, and adipokines levels in women with multiple sclerosis: possible relations with fatigue and quality of lifeEndocrine20175726227128616851
   PubMed Web of Science ®Google Scholar
• HeesenCKoehlerGGrossRTessmerWSchulzKHGoldSMAltered cytokine responses to cognitive stress in multiple sclerosis patients with fatigueMult Scler200511515715732267
   PubMed Web of Science ®Google Scholar
• Pokryszko-DraganAFrydeckaIKosmaczewskaAStimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosisClin Neurol Neurosurg20121141153115822425464
   PubMed Web of Science ®Google Scholar
• MuleroPAlmansaRNeriMJImprovement of fatigue in multiple sclerosis by physical exercise is associated to modulation of systemic interferon responseJ Neuroimmunol201528081125773148
   PubMed Web of Science ®Google Scholar
• KosticMZivkovicNCvetanovicAStojanovicIColicMIL-17 signaling in astrocytes promotes glutamate excitotoxicity: indications for the link between inflammatory and neurodegenerative events in multiple sclerosisMult Scler Relat Disord201711121728104249
   PubMed Web of Science ®Google Scholar
• MalekzadehAvan de Geer-PeetersWde GrootVTeunissenCEBeckermanHFatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?Dis Markers2015201575831425722532
   PubMed Web of Science ®Google Scholar
• BertoloneKCoylePKKruppLBDoscherCACytokine correlates of fatigue in multiple sclerosisNeurology199343A356
   Web of Science ®Google Scholar
• JafarzadehAJamaliMMahdaviRCirculating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment programJ Mol Neurosci20155589189725326790
   PubMed Web of Science ®Google Scholar
• Alvarenga-FilhoHSallesMHyginoJFatigue favors in vitro Th1 and Th17-like cell expansion and reduces corticoid sensitivity in MS patientsJ Neuroimmunol2017303818928065580
   PubMed Web of Science ®Google Scholar
• YaldizliOKumarMVagoSKreuzfelderELimmrothVPutzkiNFatigue is not associated with impaired function of regulatory T cells in untreated patients with multiple sclerosisEur Neurol20096232132619752558
   PubMed Web of Science ®Google Scholar
• GiovannoniGThompsonAJMillerDHThompsonEJFatigue is not associated with raised inflammatory markers in multiple sclerosisNeurology20015767668111524478
   PubMed Web of Science ®Google Scholar
• Adamczyk-SowaMSowaPAdamczykJEffect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantroneJ Physiol Pharmacol20166723524227226183
   PubMed Web of Science ®Google Scholar
• LosyJMichałowska-WenderGIn vivo effect of interferon-β 1a on interleukin-12 and TGF-β1 cytokines in patients with relapsing-remitting multiple sclerosisActa Neurol Scand2002106444612067328
   PubMed Web of Science ®Google Scholar
• ZhangXMarkovic-PleseSInterferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosisClin Neurol Neurosurg201011264164520570038
   PubMed Web of Science ®Google Scholar
• RamgolamVSMarkovic-PleseSInterferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosisEndocr Metab Immune Disord Drug Targets20101016116720384573
   PubMedGoogle Scholar
• RamgolamVSShaYJinJZhangXMarkovic-PleseSIFN-β inhibits human Th17 cell differentiationJ Immunol20091835418542719783688
   PubMed Web of Science ®Google Scholar
• Oreja-GuevaraCRamos-CejudoJAroeiraLSChamorroBDiez-TejedorETH1/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumabBMC Neurol2012129522989378
   PubMed Web of Science ®Google Scholar
• MillsEAOgrodnikMAPlaveAMao-DraayerYEmerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosisFront Neurol20189529410647
   PubMed Web of Science ®Google Scholar
• SuKZengPLiangWFTY720 attenuates angiotensin II-induced podocyte damage via inhibiting inflammatory cytokinesMediators Inflamm20172017370138528270699
   PubMed Web of Science ®Google Scholar
• BalasaRISimuMVoidazanSNatalizumab changes the peripheral profile of the Th17 panel in MS patients: new mechanisms of actionCNS Neurol Disord Drug Targets2017161018102628782487
   PubMed Web of Science ®Google Scholar
• Bar-OrAPachnerAMenguy-VacheronFKaplanJWiendlHTeri-flunomide and its mechanism of action in multiple sclerosisDrugs20147465967424740824
   PubMed Web of Science ®Google Scholar
• YildizMTettenbornBPutzkiNMultiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetateEur Neurol20116523123221454981
   PubMed Web of Science ®Google Scholar
• HeDGuoRZhangFZhangCDongSZhouHRituximab for relapsing-remitting multiple sclerosisCochrane Database Syst Rev201312CD009130
   Google Scholar
• HoepnerRFaissnerSSalmenAGoldRChanAEfficacy and side effects of natalizumab therapy in patients with multiple sclerosisJ Cent Nerv Syst Dis20146414924855407
   PubMedGoogle Scholar
• StephensonJSKernDMAgarwalSSImpact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal studyHealth Qual Life Outcomes20121015516423270428
   PubMed Web of Science ®Google Scholar
• SvenningssonAFalkECeliusEGNatalizumab treatment reduces fatigue in multiple sclerosis: results from the TYNERGY trial – a study in the real life settingPLoS One20138e5864323555589
   PubMed Web of Science ®Google Scholar
• IaffaldanoPViterboRGPaolicelliDImpact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational studyPLoS One20127e3584322558238
   PubMed Web of Science ®Google Scholar
• MasingueMDebsRMaillartEFatigue evaluation in fingoli-mod treated patients: an observational studyMult Scler Relat Disord20171481128619437
   PubMed Web of Science ®Google Scholar
• ShusterEAHormonal influences in multiple sclerosisCurr Top Microbiol Immunol200831826731118219822
   PubMed Web of Science ®Google Scholar
• PelfreyCMCotleurACLeeJCRudickRASex differences in cytokine responses to myelin peptides in multiple sclerosisJ Neuroimmunol200213021122312225904
   PubMed Web of Science ®Google Scholar
• SegalBMCohenJAAntelJAmericas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: environmental factors, genetics, and epigenetics in MS susceptibility and clinical courseMult Scler2018244529307302
   PubMed Web of Science ®Google Scholar
• ChalahMAAyacheSSPsychiatric event in multiple sclerosis: could it be the tip of the iceberg?Rev Bras Psiquiatr20173936536828355344
   PubMed Web of Science ®Google Scholar
• ChalahMAAyacheSSAlexithymia in multiple sclerosis: a systematic review of literatureNeuropsychologia2017104314728764994
   PubMed Web of Science ®Google Scholar
• HughesAJDunnKMChaffeeTSleep disturbance and cognitive dysfunction in multiple sclerosis: a systematic reviewCurr Neurol Neurosci Rep201818229380072
   PubMed Web of Science ®Google Scholar